ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Down 46.6% in March

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a significant decrease in short interest in March. As of March 13th, there was short interest totaling 5,007 shares, a decrease of 46.6% from the February 26th total of 9,382 shares. Based on an average daily trading volume, of 23,217 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the company’s shares are sold short.

Institutional Trading of ALPS Medical Breakthroughs ETF

Large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the fourth quarter worth $26,000. Comerica Bank purchased a new position in shares of ALPS Medical Breakthroughs ETF during the third quarter valued at $27,000. Global Retirement Partners LLC acquired a new position in ALPS Medical Breakthroughs ETF during the fourth quarter valued at $34,000. Raymond James Financial Inc. acquired a new position in ALPS Medical Breakthroughs ETF during the second quarter valued at $82,000. Finally, Ally Invest Advisors Inc. purchased a new stake in ALPS Medical Breakthroughs ETF in the 2nd quarter worth about $200,000.

ALPS Medical Breakthroughs ETF Price Performance

ALPS Medical Breakthroughs ETF stock opened at $49.90 on Friday. ALPS Medical Breakthroughs ETF has a fifty-two week low of $22.33 and a fifty-two week high of $54.79. The firm’s 50 day simple moving average is $50.95 and its 200-day simple moving average is $47.20.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.